Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion.

Conclusion. Approximately 30% of patients showed low response to ranibizumab after the loading phase and after 1 year of treatment. Two-thirds of patients that were low-responders after the loading phase remained low-responders after 1 year. PMID: 28044102 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/28044102?dopt=Abstract

Source: Journal of Ophthalmology - January 5, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research